TY - JOUR
T1 - Effects of amines on percutaneous absorption of alendronate
AU - Whang, Jiae
AU - Gwak, Hyesun
PY - 2011/5
Y1 - 2011/5
N2 - Objective: The aim of this study was to examine the effects of amines on the permeation of alendronate using solution formulations and pressure-sensitive adhesive (PSA) transdermal delivery systems (TDS). Materials and methods: Monoethanolamine (MEA), diethanolamine (DEA), triethanolamine (TEA), diethylamine (DEYA), and triethylamine (TEYA) at concentrations of 3, 6, and 10% were added to propylene glycol (PG) containing 6% caprylic acid. In vitro and in vivo experiments were conducted using alendronate solution and PSA TDS formulations. Results: When using saturated solution formulations, 3% TEA and 10% DEYA showed high permeation rates of 8.20±0.80 and 7.87±0.18 μg/cm2/h, respectively. The maximum permeation flux of 1.79±0.28 μg/cm2/h from 1mg/ml solution was obtained with the addition of 10% DEYA followed by the addition of 10% TEYA (1.72±0.72 μg/cm2/h). The highest enhancement factor of 1.86 was obtained with alendronate PSA TDS containing 10% MEA compared with no amine. In the in vivo study, the amount remaining to be excreted (ARE) at time 0 (Ae∞) and ARE at time t [Ae(t)] differed between TDS and oral delivery significantly (P<0.01). The TDS containing 10% MEA showed the highest Ae∞ (19.5±6.93 μg), which was 2.7- and 2.2-fold, compared with oral and no amine administration, respectively. Conclusion: Based on the results, TDS with 10% MEA in PG containing 6% caprylic acid could be a good candidate for the alendronate TDS.
AB - Objective: The aim of this study was to examine the effects of amines on the permeation of alendronate using solution formulations and pressure-sensitive adhesive (PSA) transdermal delivery systems (TDS). Materials and methods: Monoethanolamine (MEA), diethanolamine (DEA), triethanolamine (TEA), diethylamine (DEYA), and triethylamine (TEYA) at concentrations of 3, 6, and 10% were added to propylene glycol (PG) containing 6% caprylic acid. In vitro and in vivo experiments were conducted using alendronate solution and PSA TDS formulations. Results: When using saturated solution formulations, 3% TEA and 10% DEYA showed high permeation rates of 8.20±0.80 and 7.87±0.18 μg/cm2/h, respectively. The maximum permeation flux of 1.79±0.28 μg/cm2/h from 1mg/ml solution was obtained with the addition of 10% DEYA followed by the addition of 10% TEYA (1.72±0.72 μg/cm2/h). The highest enhancement factor of 1.86 was obtained with alendronate PSA TDS containing 10% MEA compared with no amine. In the in vivo study, the amount remaining to be excreted (ARE) at time 0 (Ae∞) and ARE at time t [Ae(t)] differed between TDS and oral delivery significantly (P<0.01). The TDS containing 10% MEA showed the highest Ae∞ (19.5±6.93 μg), which was 2.7- and 2.2-fold, compared with oral and no amine administration, respectively. Conclusion: Based on the results, TDS with 10% MEA in PG containing 6% caprylic acid could be a good candidate for the alendronate TDS.
KW - Alendronate
KW - amines
KW - permeation flux
KW - pharmacokinetics
KW - transdermal delivery system
UR - http://www.scopus.com/inward/record.url?scp=79953785247&partnerID=8YFLogxK
U2 - 10.3109/03639045.2010.525237
DO - 10.3109/03639045.2010.525237
M3 - Article
C2 - 21126206
AN - SCOPUS:79953785247
SN - 0363-9045
VL - 37
SP - 491
EP - 497
JO - Drug Development and Industrial Pharmacy
JF - Drug Development and Industrial Pharmacy
IS - 5
ER -